Medincell annual stock-based compensation
2021
2022
2023
2024
2025
2026
Medincell Stock-Based Compensation Growth & History (MEDCL)
Medincell's stock-based compensation was €5.2M for fiscal 2026.
View full Medincell company overviewMedincell annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | €5.2M | €2.2M | +75.89% |
| 2025 | 2025-03-31 | €3.0M | €153,000 | +5.45% |
| 2024 | 2024-03-31 | €2.8M | €530,000 | +23.26% |
| 2023 | 2023-03-31 | €2.3M | −€115,000 | −4.80% |
| 2022 | 2022-03-31 | €2.4M | €831,000 | +53.17% |
| 2021 | 2021-03-31 | €1.6M | — | — |
Medincell stock-based compensation trends
Over the last five fiscal years, Medincell's stock-based compensation increased from €1.6M to €5.2M, a change of €3.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
reported stock-based compensation
TickerStat standardizes share-based compensation reported in company official filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medincell source filings ↗